This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundCurrent evidence suggests that cardiovascular disease (CVD) plays a role in the progression of chronic obstructive pulmonary disease (COPD). However, the relationship between CVD and the severity of COPD remains inadequately understood.
Patients with more severe obesity were more likely to have responder characteristics for atrial shunt therapy (fewer pacemakers and lower exercise pulmonary vascular resistance [PVR]). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Introduction:The demographics of patients with pulmonary arterial hypertension (PAH) is shifting towards older age, increased comorbidity burden, and an increase in the risk of left ventricular (LV) diastolic dysfunction. Results:Overall, 140 participants were identified (age: 56±16 years; BMI: 30.04±8.04
Association between body mass index (BMI) and clinical outcomes in PARADISE-MI. ( A ) Histogram for BMI (kg/m 2 ), ( B ) adverse events for BMI subgroups, and spline model curves for ( C ) the primary composite outcome and ( D ) cardiovascular (CV) death by BMI subgroups. 100 patient-years for BMI 40kg/m 2 ).
Asthma significantly increased the prevalence of stroke among participants aged 1844 years old, with a BMI 18.5029.99kg/m2, with low education levels, and with a PIR<1.00. Asthma also increased the prevalence of angina in females, non-Hispanic Blacks, participants aged 4559 years old, with a BMI30.00kg/m2, and with a PIR<1.00.
Further regression analysis indicated that body mass index (BMI) might be related to changes in LAD. Additionally, the use of digoxin could affect changes in left ventricular ejection fraction.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content